Machsanei Hashuk Integrates WalkOut’s Smart-cart Solution in All Its Branches
9.12.2021 20:53:00 EET | Business Wire | Press release
The Israeli company WalkOut, the developer of an autonomous end-to-end frictionless shopping solution, announces an extensive cooperation agreement with Machsanei Hashuk, one of the largest supermarket chains in Israel. As part of the agreement, the chain will implement the fully autonomous checkout solution, considered the most accurate in the world's retail industry, in all 62 of its branches. Its deployment will begin as early as next month.
Although 61 percent of shoppers would prefer to purchase brands that also have a physical location, over 70 percent of shoppers report that standing in line for checkouts is frustrating and detracts from the shopping experience. Until the development of WalkOut’s solution, no system has accompanied the customer throughout the entire purchase, which includes actual checkout.
WalkOut’s retrofit smartcart solution offers a revolution in the shopping experience that addresses two main challenges that marketing chains face in the physical buying process.
The first is related to waiting in long queues at the checkout. The second is the inability to create a personalized shopping experience for each customer.
The company’s first-ever truly seamless retrofitted solution in the retail industry requires no costly infrastructural changes to the store, while other solutions require the retailer to purchase new carts and most rely on barcode scanners and scales for item recognition. The mountable cart device's multiple high-precision cameras, which utilize many different proprietary algorithms to accurately recognize products, identify the items as shoppers load or remove them with 99.2 percent accuracy.
WalkOut’s edge computing and machine-vision algorithms also curtail the need for costly on-cloud servers and high-bandwidth internet support. This use of single-sensor architecture and edge-computing allows retail stores to operate a much more robust and cost-effective solution. Through a large touchscreen, the device also communicates with the customer to offer personalized recommendations, store navigation, supplementary product information, and relevant promotions based on the shopper's history and location in the store.
"Connecting to one of the largest retail chains in Israel is an exciting opportunity and an important milestone for us," says Assaf Gedalia, CEO and Co-Founder of WalkOut. “The solution is futuristic, personalized, and at the same time preserves the customer's privacy."
"As a chain that advocates innovative technologies, we wanted to offer our customers significant savings in waiting times at the checkouts and provide a more personal, accessible and efficient shopping experience," said Shalom Naaman, CEO and Owner of Machsanei Hashuk. "The WalkOut solution will significantly shorten the length of stay in the branches, help maximize our operational efficiency, and allow us to offer one of the most advanced shopping experiences in the world."
About WalkOut
WalkOut, founded in 2018, has set itself the goal of changing the way consumers purchase products in physical stores by placing the checkout directly on the shopping cart. The company's solution is based on machine vision technology capable of identifying any item placed or removed from the cart and calculating it in the final payment. In this way, the cart eliminates the need for a checkout and reduces the duration of the payment process to a minimum. The WalkOut solution includes a large touch screen located on the cart and combines a personalized shopping experience with offers and promotions based on each consumer's preferences, complementary products and the location of the products in the store. The WalkOut system is modular and can be installed on existing carts in stores without the need for significant changes on the part of the store.
About Machsanei Hashuk
Machsanei Hashuk is a leading marketing chain owned and managed by the Naaman & Cohen families that was first established in 1996 in the city of Beer Sheva. The chain currently has 62 branches nationwide from Safed to Eilat. In 2019, the chain acquired Co-op, and in doing so became one of the largest leading marketing chains in Israel. Co-op branches have since been converted into "Machsanei Hashuk sheli''. The chain operates an advanced and accessible online site, in addition to its branches. It also offers its own Wincard+ credit card, in cooperation with Max, which combines regular card rewards with the chain's own promotions. Machsanei Hashuk operates a strong and active customer club with more than 400,000 loyal customers.
The chain is the official sponsor of the football team "Hapoel Machsanei Hashuk Beer-Sheva.” For more information, visit https://www.mck.co.il/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005892/en/
Contact information
Media Contact
Lea Berdugo
ReBlonde for WalkOut
lea@reblonde.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
